Lancet
-
Comparative Study Clinical Trial
Effect of desferrioxamine on removal of aluminum and iron by coated charcoal haemoperfusion and haemodialysis.
An intravenous infusion of desferrioxamine (3 g) was given to 17 chronic renal failure patients stabilised on standard haemodialysis. Aluminium clearance 48 h after desferrioxamine was 65.3 +/- 11.0 ml/min for 'Dialaid 4000' with 70 g coated charcoal haemoperfusion system; 44.6 +/- 13.7 ml/min for 'Rhondial 75' with polyacrylonitrate membrane; 35.8 +/- 11.0 ml/min for 'Monitral' with polyacrylonitrate membrane; and 4.0 +/- 17.8 ml/min for haemodialysers with a 'Cupraphane' membrane. ⋯ CAC did not absorb ferric ions in vitro. But when 40 mg/dl of desferrioxamine was present CAC absorbed increasing concentrations of ferric ions in a linear fashion.
-
Comparative Study
Neoplasia of the cervix uteri and contraception: a possible adverse effect of the pill.
The incidence of biopsy-proven cervical neoplasia during a 10-year follow-up was determined in 6838 parous women who entered the Oxford-Family Planning Association contraceptive study while using oral contraceptives and 3154 parous women who entered the study while using an intrauterine device (IUD). Risk factors for cervical neoplasia, continuation of attendance at family planning clinics, and frequency of examination by cervical cytology were similar in the two groups. All 13 cases of invasive cancer occurred in women in the oral contraceptive group; 9 had more than 6 years' use of the pill. ⋯ Amongst IUD users, there was no such trend in incidence with duration of use: the rate fluctuated around 1.0 per 1000 woman-years. The great majority of cases of invasive cancer were detected by means of cervical smears and were treated while the disease was still curable. Long-term users of oral contraceptives should have regular cervical cytological examination.